A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

Federal health officials aim to speed up drug development and better compete with China.

HHS launches clinical trial reforms — including new pilot programs and updated FDA guidance — to accelerate US drug development and compete with China.